Overview Request Sample Pages Request Customization Download PDF
You are viewing: Japan Companion Diagnostics Market analysis
Part of: Companion Diagnostics Market (Global)

The Japan Companion Diagnostics Market was valued at $413.1 Million in 2026 and projected to reach to $665.8 Million by 2031, representing a compound annual growth rate of 16.9%. Japan's companion diagnostics market is poised for sustained growth through 2031, driven by the convergence of an aging population, advanced healthcare infrastructure, and strong government commitment to precision medicine.

Japan Companion Diagnostics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Companion Diagnostics Market Trends and Insights

  • Japan's market growth significantly outpaces the global average of 12.9% CAGR, driven by the country's advanced healthcare infrastructure, aging population, and strong emphasis on precision medicine.
  • Japan's pharmaceutical and diagnostic sectors are increasingly integrating companion diagnostics into oncology and personalized treatment pathways, reflecting the nation's commitment to innovative healthcare solutions. The forecast period through 2031 positions Japan as a critical market within Asia Pacific for companion diagnostics adoption.
  • Japan's regulatory environment and reimbursement policies continue to support market expansion, while Japanese healthcare providers prioritize biomarker-driven treatment strategies.
  • Japan's 16.9% CAGR underscores the country's leadership in diagnostic innovation and the growing clinical demand for targeted therapeutic approaches across major disease areas..

Key Market Statistics

  • CAGR (2026-2031) 16.9% CAGR
  • Market Size, 2026 ~USD 413.1 Million
  • Forecast, 2031 ~USD 665.8 Million
  • Country Japan

Japan Companion Diagnostics Market Overview

Rapid Market Expansion :

Japan's companion diagnostics market is projected to grow from $413.1 million in 2026 to $665.8 million by 2031, representing a robust 16.9% CAGR that significantly outpaces the global average of 12.9%.

Aging Population Driving Demand :

Japan's rapidly aging demographic profile is accelerating the adoption of companion diagnostics for personalized cancer treatment and chronic disease management, creating sustained market growth opportunities.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system, coupled with strong government support for precision medicine initiatives, positions the country as a leader in companion diagnostic adoption and innovation in Asia.

Pharmaceutical Sector Integration :

Japan's robust pharmaceutical and diagnostic sectors are increasingly collaborating to develop integrated companion diagnostic solutions, enhancing treatment efficacy and patient outcomes across multiple therapeutic areas.

Japan Companion Diagnostics Market Dynamics

  • The market's 16.9% CAGR reflects Japan's leadership in adopting personalized healthcare solutions and the increasing integration of diagnostics with pharmaceutical development.
  • Regulatory support from Japanese authorities and rising healthcare expenditure will further accelerate market penetration across oncology, cardiovascular, and infectious disease segments.
  • Strategic partnerships between domestic and international diagnostic companies will enhance innovation and market accessibility..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Japan's companion diagnostics market is valued at $413.1 million in 2026 and will grow to $665.8 million by 2031, representing a 16.9% CAGR.
      • Japan's market growth rate exceeds the global CAGR of 12.9%, positioning Japan as a high-growth region within Asia Pacific.
      • Japan's aging population and advanced healthcare infrastructure drive adoption of precision medicine and biomarker-driven diagnostics.
      • Japan's regulatory framework and reimbursement policies support sustained expansion of companion diagnostics through 2031.

      Companion Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment NEXT-GENERATION SEQUENCING (Technology)
      Forecast Period 2026–2031
      Growth Rate CAGR of 12.9% from 2026 to 2031
      Largest Segment CANCER (Indication)
      Market Size Base Year (Billions) ~USD 6.31 (2026)
      Revenue Forecast (Billions) ~USD 11.57 (2031)
      Segments Covered Product & Service, Technology, Indication, Type, Sample Type, End User

      Japan Companion Diagnostics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product & Service

      • Assays, Kits, And Reagents
      • Instruments & Systems
      • Software & Services

      By Technology

      • Immunohistochemistry
      • In Situ Hybridization
      • Next-Generation Sequencing
      • Other Technologies
      • Polymerase Chain Reaction

      By Indication

      • Cancer
      • Cardiovascular Diseases
      • Infectious Diseases
      • Neurological Diseases
      • Other Indications

      By Type

      • Blood Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Other Cancer Types
      • Other Cancers

      By Sample Type

      • Blood Samples
      • Other Sample Types
      • Tissue Samples

      By End User

      • Contract Research Organizations
      • Other End Users
      • Pharmaceutical & Biopharmaceutical Companies
      • Pharmaceutical & Biotechnology Companies
      • Reference Laboratories

      Target Audience

      • Pharmaceutical Companies : Develop companion diagnostic strategies aligned with Japan's precision medicine initiatives and regulatory requirements to enhance drug development and market commercialization success.
      • Diagnostic Manufacturers : Evaluate Japan's high-growth market potential and competitive landscape to inform product development, market entry strategies, and partnership opportunities in Asia's advanced healthcare market.
      • Healthcare Investors & PE Firms : Assess investment opportunities in Japan's companion diagnostics sector, including market growth drivers, valuation benchmarks, and exit potential in this high-CAGR healthcare segment.
      • Hospital & Clinical Networks : Understand companion diagnostic adoption trends and clinical integration pathways to optimize precision medicine programs and improve patient outcomes in Japan's healthcare system.
      • Market Research & Strategy Consultants : Access comprehensive Japan-specific market data to support client advisory services, competitive analysis, and strategic recommendations in the companion diagnostics sector.

      Key Companies in the Japan Companion Diagnostics Market

      CompanyHQOwnershipStrongest segments
      CLARITY PHARMACEUTICALSAustraliaPublic CompanySAR-bisPSMA theranostic platform,SAR-Bombesin pan-cancer theranostics,SARTATE (SSTR2-targeted theranostics),
      FOUNDATION MEDICINEUnited StatesPrivate CompanyFoundationOne CDx (tissue-based solid tumor CGP),FoundationOne Liquid CDx (blood-based solid tumor CGP),Hematologic malignancy / sarcoma / other LDTs,
      GEUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,
      GENOMIC HEALTH INCUnited StatesPrivate CompanyOncotype DX Breast Recurrence Score and related breast assays,Oncotype DX Colon and prostate cancer assays,Other genomic and emerging epigenomic decision-support services,
      MEDICAL & BIOLOGICAL LABORATORIES CO.JapanPrivate CompanyAllergy in vitro diagnostics,Autoimmune and skin disease diagnostics,COVID-19 and respiratory diagnostics,
      ROSETTA GENOMICSIsraelPublic CompanymicroRNA-based oncology tests (RosettaGX Cancer Origin, mi-KIDNEY, RosettaGX Reveal, mi-LUNG),FISH-based assays (UroVysion, ERG/PTEN, ALK/ROS1),PCR gene mutation analysis (bladder, lung, colon, melanoma),
      TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls and petrochemicals (VCM, ethylene, propylene, aromatics, EDC),Polymers and synthetic rubbers (EVA, PE, functional polymers, PVC pastes),
      DIASORINItalyPublic CompanyImmunodiagnostics (LIAISON XL / LIAISON XS),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other IVD solutions,
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products (lab, transfusion, molecular, point-of-care, rapid tests),Medical Devices (cardiovascular, diabetes care, neuromodulation, vascular, structural heart),Nutritional Products (pediatric, adult, infant formula),
      DANAHERUnited StatesPublic CompanyBiotechnology (Bioprocessing & Single-Use),Life Sciences Tools & Genomics,Diagnostics,
      GUARDANT HEALTHUnited StatesPublic CompanyGuardant360 portfolio (CDx, Liquid, Tissue),Shield colorectal cancer screening,Minimal residual disease and recurrence (Guardant Reveal),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
      BIOMéRIEUXFrancePublic CompanyBIOFIRE & SPOTFIRE multiplex/lowplex PCR,VITEK (2, MS, REVEAL) ID/AST systems,BACT/ALERT VIRTUO & blood culture,
      ICON PLCIrelandPublic CompanyFull-service clinical development (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory, bioanalytical, biomarker, and vaccine testing,
      MYRIAD GENETICS, INC.United StatesPublic CompanyHereditary and oncology diagnostics (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Women’s health and reproductive genetics (Prequel, Foresight, SneakPeek, FirstGene),Pharmacogenomics and mental health (GeneSight Psychotropic),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx and related),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,
      ABNOVA CORPORATIONTaiwanPublic CompanyAntibodies (mono/polyclonal, recombinant, circulating rare cell),Proteins/Peptides, Lysates/Slides, Beads/Dyes, Ab Arrays,Medical Diagnostic Instruments, Systems, and Automation,

      CLARITY PHARMACEUTICALS

      Clarity Pharmaceuticals is an Australian public company founded in 2010 that employs 88 people. The company operates in the pharmaceutical sector.

      FOUNDATION MEDICINE

      Foundation Medicine is a United States-based private company established in 2009 with 662 employees. The company operates in the pharmaceutical and biotechnology industry.

      GE

      GE is a United States public company founded in 1892 with 57,000 employees. The company is a diversified conglomerate operating across multiple industrial sectors.

      GENOMIC HEALTH INC

      Genomic Health Inc. is a United States-based private company founded in 2000 with 829 employees. The company operates in the genomics and biotechnology sector.

      MEDICAL & BIOLOGICAL LABORATORIES CO.

      Medical & Biological Laboratories Co. is a Japan-based private company founded in 1969 with 408 employees. The company operates in the medical and biological laboratory sector.

      ROSETTA GENOMICS

      Rosetta Genomics is an Israel-based public company established in 2000 with 86 employees. The company operates in the genomics and molecular diagnostics sector.

      TOSOH CORPORATION

      Tosoh Corporation is a Japan-based public company founded in 1935 with 14,850 employees. The company operates across multiple sectors including chemicals, pharmaceuticals, and diagnostics.

      DIASORIN

      DiaSorin is an Italy-based public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

      GE HEALTHCARE

      GE Healthcare is a United States-based public company founded in 2022 with 54,000 employees. The company operates in the healthcare technology and diagnostics industry.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company operates in life sciences, diagnostics, and applied chemical markets.

      QIAGEN

      QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. The company operates in molecular diagnostics and life sciences research.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and software.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutrition.

      DANAHER

      Danaher is a United States-based public company founded in 1969 with 59,000 employees. The company operates across life sciences, diagnostics, environmental, and applied solutions sectors.

      GUARDANT HEALTH

      Guardant Health is a United States-based public company founded in 2011 with 2,498 employees. The company operates in precision oncology and liquid biopsy diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.

      BIOMéRIEUX

      bioMérieux is a France-based public company founded in 1963 with 14,894 employees. The company operates in in vitro diagnostics and microbiology testing.

      ICON PLC

      ICON PLC is an Ireland-based public company founded in 1989 with 40,350 employees. The company provides clinical research and development services to the pharmaceutical and biotechnology industries.

      MYRIAD GENETICS, INC.

      Myriad Genetics, Inc. is a United States-based public company founded in 1991 with 2,700 employees. The company operates in molecular diagnostics and personalized medicine.

      SYSMEX CORPORATION

      Sysmex Corporation is a Japan-based public company founded in 1968 with 10,861 employees. The company operates in clinical laboratory diagnostics and life sciences.

      ABNOVA CORPORATION

      Abnova Corporation is a Taiwan-based public company founded in 2002. The company operates in the biotechnology and life sciences research sector.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation data for Japan ($413.1M in 2026, $665.8M in 2031) with verified 16.9% CAGR to support investment decisions and business planning in the region.
      • Competitive Landscape Intelligence : Understand Japan-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies tailored to the Japanese healthcare ecosystem.
      • Regulatory & Reimbursement Insights : Access Japan-specific regulatory pathways, reimbursement frameworks, and government policies driving companion diagnostic adoption to navigate market entry and commercialization strategies effectively.
      • Demographic & Clinical Trends : Leverage data on Japan's aging population, disease prevalence, and precision medicine adoption patterns to identify high-growth therapeutic segments and target customer segments.
      • Strategic Growth Opportunities : Identify emerging opportunities in Japan's companion diagnostics market, including unmet clinical needs, technology gaps, and partnership potential with pharmaceutical and healthcare organizations.

      Frequently asked questions

      What is the current size of Japan's companion diagnostics market?

      Japan's companion diagnostics market is estimated at $413.1 million in 2026 and is projected to reach $665.8 million by 2031.

      What is the CAGR for Japan's companion diagnostics market?

      Japan's companion diagnostics market is expected to grow at a CAGR of 16.9% from 2026 to 2031, outpacing the global average.

      Why is Japan's companion diagnostics market growing faster than the global average?

      Japan's advanced healthcare infrastructure, aging population, strong regulatory support, and emphasis on precision medicine drive faster market growth compared to global trends.

      Which therapeutic areas are driving Japan's companion diagnostics adoption?

      Oncology and personalized medicine are primary drivers of companion diagnostics adoption in Japan, supported by biomarker-driven treatment strategies.

      How does Japan's reimbursement environment support companion diagnostics growth?

      Japan's regulatory framework and reimbursement policies increasingly recognize and support companion diagnostics, facilitating market expansion through 2031.

      RESEARCH METHODOLOGY

      This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

      Secondary Research

      Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global companion diagnostics market, and the findings were validated through primary research.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

      Companion Diagnostics Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The global size of the companion diagnostics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Companion Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

      Market Definition

      A companion diagnostic (CDx) is an in vitro diagnostic (IVD) device that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug provides information essential for the safe and effective use of a specific therapeutic product, particularly targeted therapies and biologics. These tests help identify patients who are most likely to benefit from a treatment, may experience adverse reactions, or require therapy selection based on biomarker or molecular profiling. The market includes assay kits, reagents, instruments, software, and laboratory testing services across technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization, among others.

      Key Stakeholders

      • Manufacturers and Distributors of Companion Diagnostics Products
      • In Vitro Diagnostic (IVD) Companies
      • Hospital Laboratories
      • Diagnostic Laboratories
      • Diagnostics Suppliers
      • Pharmaceutical Companies
      • Research Laboratories and Academic Institutes
      • Clinical Research Organizations (CROs)
      • Research & Development (R&D) Companies
      • Academic Medical Centers/Government Research Organizations
      • Companion Diagnostics Service Providers
      • Government Associations
      • Market Research & Consulting Firms
      • Venture Capitalists & Investors

      Report Objectives

      • To define, describe, segment, and forecast the global companion diagnostics market, by product & service, technology, Indication, Sample type, Drug Class Associated with CDX, Application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
      • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the report:

      Geographical Analysis

      • Further breakdown of the Rest of Europe companion diagnostics market, by country
      • Further breakdown of the Rest of Asia Pacific companion diagnostics market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Segment Analysis

      • Cross-segment analysis

       

      Get the Full Companion Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Companion Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status